Articles about Puma Biotechnology
PUMA BIOTECHNOLOGY, INC. : Other Events (form 8-K) -December 16, 2022 at 04:18 pm EST | MarketScreener
Puma Biotechnology, Inc.
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology, Inc. (PBYI) Price, Charts, Market Cap, Markets, Exchanges, PBYI to USD Calculator
Puma Biotechnology Inc. Advanced Charts | PBYI | Barron's
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
PBYI Insider Trading Activity - Puma Biotechnology, Inc.
Puma Biotechnology, Inc. (NASD:PBYI) Seasonal Chart | Equity Clock
Puma Biotechnology (PBYI) - 5 Price Charts 2012-2023 (History)
Praneeth C. - Senior Clinical Data Manager - Exelixis | LinkedIn
PBYI Stock Price and Chart — NASDAQ:PBYI — TradingView
Why Puma Biotechnology, Inc. Stock Crashed 37% in March
Puma Biotech granted Orphan Drug status for lung cancer candida | Seeking Alpha
Puma Biotechnology Inc - AnnualReports.com
Puma Biotechnology's (PBYI) 52 Week High at $5.08 & Low at $2.14
Puma Biotechnology, Inc. - SEC Filings - Annual Reports & Proxies
Puma Biotechnology (PBYI) Price Target Increased by 5.26% to 5.10
Puma Biotechnology
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
